A landmark randomized controlled trial published in The New England Journal of Medicine has demonstrated that finerenone, a non-steroidal mineralocorticoid receptor antagonist, provides significant cardiovascular benefits in non-diabetic chronic kidney disease patients. The FIND-CKD trial enrolled 5,674 patients across international centers and found that finerenone reduced major cardiovascular events by 14% compared to placebo, with benefits observed consistently across multiple kidney disease stages and etiologies. This represents a substantial expansion of finerenone’s clinical utility, previously established only in diabetic kidney disease populations. Importantly, the medication maintained a favorable safety profile with manageable hyperkalemia risk through appropriate monitoring. These findings suggest that millions of non-diabetic patients with chronic kidney disease worldwide could benefit from this therapeutic approach, potentially transforming standard treatment protocols in nephrology and cardiology practice.
Read the full article on GMJ Newsroom.
Was this article helpful?
